Bausch Health subsidiary secures RAMQ formulary listing for PrOKEDI

2026-07-12
Bausch Health subsidiary secures RAMQ formulary listing for PrOKEDI

Bausch Health's Canadian subsidiary has successfully listed PrOKEDI dosages on the RAMQ formulary, expanding access to the treatment in Quebec.

Expansion of PrOKEDI access in Quebec

The Canadian subsidiary of Bausch Health Companies Inc. (NYSE: BHC) has confirmed that specific dosages of PrOKEDI are now included in the Régie de l'assurance maladie du Québec (RAMQ) formulary. This administrative inclusion facilitates broader access to the treatment for patients within the province of Quebec.

The RAMQ formulary serves as a critical mechanism for determining which medications are covered under the provincial public drug insurance plan. By securing this listing, Bausch Health ensures that clinicians and patients in the region have a streamlined pathway to access PrOKEDI under provincial coverage frameworks.

Bausch Health market positioning

Bausch Health continues to manage a diverse portfolio of pharmaceutical products across global markets. The company, which is listed on the New York Stock Exchange, maintains a significant presence in both specialty medicines and consumer healthcare sectors.

Market analysts have recently identified the company as a point of interest within the pharmaceutical sector. While the company's stock performance is subject to various market volatility factors common to the healthcare industry, its ability to secure provincial formulary listings remains a key driver for regional revenue and patient uptake.

Strategic implications for Canadian operations

Securing formulary placement in Quebec is a strategic milestone for Bausch Health’s Canadian operations. As one of Canada's largest provinces, Quebec's drug coverage decisions heavily influence the broader accessibility of specialized therapies across the country.

The inclusion of PrOKEDI represents a targeted effort to integrate the company's therapeutic offerings into the public healthcare infrastructure. This development allows the subsidiary to focus on clinical deployment and physician engagement within the Quebec healthcare system.

Read more
Recommendations
Recommendations